Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 1/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.56 |
| ▸ | GPR3 | P46089 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30506312 | 1.00 | GLS (0.56) | GLSADORA2AADORA2BGPR3KDM4E | |
| Ammonia Solution, Strong SCHEMBL27739630 | 0.98 | GLS (0.55) | GLSADORA2AADORA2BGPR3KDM4E | |
| Hydrochloric Acid SCHEMBL29176227 | 0.96 | GLS (0.53) | GLSADORA2AADORA2BGPR3KDM4E | |
| Formamide SCHEMBL11970874 | 0.89 | GLS (0.47) | GLSADORA2AADORA2BGPR3KDM4E | |
| SCHEMBL28999290 | 0.89 | GLS (0.47) | GLSADORA2AADORA2BGPR3KDM4E | |
| SCHEMBL14493345 | 0.84 | ADORA2A (0.48) | GLSADORA2AADORA2BKDM4EMAPT | |
| SCHEMBL7737033 | 0.76 | GPR3 (0.44) | GLSGPR3KDM4EMAPTALDH1A1 | |
| SCHEMBL18463756 | 0.76 | GLS (0.50) | GLSGPR3KDM4EMAPTALDH1A1 | |
| SCHEMBL823488 | 0.76 | GSK3B (0.45) | GLSGPR3KDM4EALDH1A1HSD17B10 | |
| SCHEMBL22415815 | 0.76 | GLS (0.50) | GLSGPR3KDM4EMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 444 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104892588-B | Photochromic indazole thiophene hybrid-type perfluorinated cyclopentene compound and its synthetic method and application | 江西科技师范大学 | 2017-07-07 | — | — | CN | claimed |
| CN-104892588-A | Photochromic indazole-thiophene hybrid type perfluorinated cyclopentene compound and preparation method and application thereof | UNIV JIANGXI NORMAL SCI & TECH | 2015-09-09 | — | — | CN | claimed |
| US-RE37781-E1 | VIRICIDES, PROTEASE INHIBITOR | DUPONT PHARMACEUTICALS COMPANY | 2002-07-02 | — | — | US | claimed |
| US-5877170-A | VIRICIDES | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-03-02 | — | — | US | claimed |
| US-5610294-A | VIRAL TREATMENT | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-03-11 | — | — | US | claimed |
| US-20240208967-A1 | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | INVENTISBIO CO LTD (CN) | 2024-06-27 | — | — | US | disclosed |
| WO-2024020084-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023249872-A1 | SUBSTITUTED FUSED BICYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT | ALKERMES, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023217879-A1 | PYRROLIDIONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-16 | — | — | WO | disclosed |
| US-20230365592-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365592-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230322683-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-12 | — | — | US | disclosed |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-7238696-B2 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-07-03 | — | — | US | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1757602-A1 | VLA-4 INHIBITOR | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-20050159469-A1 | HIV protease inhibiting compounds | ABBVIE INC. | 2005-07-21 | — | — | US | disclosed |
| US-5670526-A | ANTIINFLAMMATORY AGENT, IMMUNOSUPPRESSANT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208967-A1 | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | EGFR, WEE1, DPYD | GLS 217/4885ADORA2A 1863/4885ADORA2B 1509/4885 |
| US-20230322683-A1 | HETEROCYCLIC COMPOUND | PARK7, SMN1; SMN2, SNCA | GLS 1560/4885ADORA2A 2781/4885ADORA2B 1058/4885 |
| US-20230365592-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | GLS 33/4885ADORA2A 3515/4885ADORA2B 2455/4885 |
| US-20050159469-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | GLS 1689/4885ADORA2A 4609/4885ADORA2B 4378/4885 |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, HTR3C | GLS 1149/4885ADORA2A 202/4885ADORA2B 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.